MindBio Therapeutics Corp. has completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk, a significant step toward commercializing a rapid, non-invasive alternative to conventional drug and alcohol screening. The announcement, disseminated via TechMediaWire, signals growing momentum for AI-driven voice analytics in workplace safety.
The new hardware builds on a prototype developed in June and supports the company’s proprietary Voice AI technology, which analyzes vocal characteristics to identify potential impairment. MindBio is continuing software integration, system testing, and validation of its predictive models against conventional breath alcohol and oral fluid testing methods. A potential initial commercial pilot is targeted for later this year, which would allow the technology to be evaluated in a real-world environment against existing testing methods.
MindBio, a biotechnology company developing artificial intelligence-driven voice analytics for drug and alcohol intoxication detection, aims to enable more frequent, large-scale workplace screening while potentially reducing testing costs, administration time, and operational disruptions. The company is targeting safety-sensitive industries including mining, aviation, construction, heavy transport, and law enforcement.
The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. MindBio is developing an enterprise platform including Edge-AI kiosks that integrate bespoke hardware and software for detection of drug and alcohol intoxication in a range of enterprise environments. For investors, the latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF. To view the full press release, visit https://ibn.fm/UN9LN.
The development matters because traditional testing methods can be intrusive, time-consuming, and costly, often limiting how frequently employers can screen workers. A voice-based kiosk could allow for more frequent, scalable screening without the need for bodily fluids or breath samples, potentially improving safety and reducing administrative burdens. If validated, the technology could disrupt the workplace drug testing market and expand MindBio’s reach into global safety-sensitive sectors.
TechMediaWire is a specialized communications platform within the Dynamic Brand Portfolio at IBN, providing access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. The platform offers corporate communications solutions and reaches a wide audience of investors, journalists, and the public. Full terms of use and disclaimers are available at https://www.TechMediaWire.com/Disclaimer.
